Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

European zoonotic surveillance mapped - 350,000 cases in 2006

This article was originally published in Clinica

Executive Summary

The European Food Safety Authority (EFSA) and the European Centre for Disease Prevention and Control (ECDC) have published the 2006 zoonoses report, providing details of the diagnostic testing and surveillance conducted in 24 EU member states and six non-member countries. The 310-page report (available via www.efsa.europa.eu) covers a total of 17 zoonoses - infectious diseases transmissible from animals to humans. Of the more than 350,000 cases recorded in 2006, Campylobacter infections accounted for more than half, at over 175,000 diagnoses, down from just shy of 200,000 in 2005. Salmonella followed, with 161,000 cases, down from 174,000. Listeria infections - which although far less prevalent have a high fatality rate - were up 8.6%, from 1,427 cases to 1,583 in 2006.

You may also be interested in...



QUOTED. 1 December. Rob Field.

UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.

Aducanumab Review: Looking For Precedents – Long Ago And Far Afield

The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.

The Rebate Rule May Not Last, But It Changed The Pricing Debate

Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.

Topics

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel